SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics informs about financial results

28 May 2025 Evaluate
Pursuant to SEBI Circular No SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, Lasa Supergenerics has informed that it enclosed the Integrated Filing (Financial) for the quarter and the year ended March 31, 2025.

The above information is a part of company’s filings submitted to BSE.

Lasa Supergenerics Share Price

8.16 0.27 (3.42%)
16-Apr-2026 11:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.40
Dr. Reddys Lab 1222.00
Cipla 1231.20
Zydus Lifesciences 941.55
Lupin 2318.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×